TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00450801
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
Study: NCT00450801
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
Study: NCT02947126
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 7% Hypertonic saline
Study: NCT02947126
Drug: Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 0.9% Isotonic saline
Study: NCT01089426
Drug: Omegaven™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg/d of Omegaven until discontinuation of PN
Study: NCT02242474
Drug: Anti-TNF suspended perioperatively
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242474
Drug: Anti-TNFα continued perioperatively
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05412472
Drug: GC4419
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg IV infusion of GC4419 over 60 minutes.
Study: NCT00958269
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00829257
Drug: HFA-BDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP (Qvar) 100ug 2puff b.i.d
Study: NCT00601796
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (300 mg/m\^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
Study: NCT03701568
Drug: dC/dT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collection of retrospective data from TK2 patients previously treated with dC/dT
Study: NCT02172508
Drug: Placebo Lactose Capsule
Normalized name: lactose Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01064037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion during 48h
Study: NCT00656591
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate
Study: NCT01043666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04764058
Drug: Tienam 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem and cilastatin sodium
Study: NCT04224428
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose oral tablet
Study: NCT03955601
Drug: Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''
Approvals — FDA: no, EMA: no, PMDA: no
Description: ''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment , ''ATG'' will be used to reduce GVHD and facilitate engraftment while ''combine PBSC'' and/OR ''Bone marrow harvest'' will be used
Study: NCT00391417
Drug: estradiol gel
Normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03774082
Drug: INC424
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib is taken orally either as 5mg tablets or as pediatric formulation (dosage based on age group)
Study: NCT03589885
Drug: Placebo 2 mL auto-injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Study: NCT03589885
Drug: Placebo 1 mL prefilled syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Study: NCT03519516
Drug: PRO-174
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle
Study: NCT03519516
Drug: Sophixín Ofteno®
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Active substance: Ciprofloxacin 0.3%~* Pharmaceutical form: Ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle
Study: NCT00171314
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
Study: NCT00042250
Drug: Chemotherapy for hematologic malignancy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01096043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An infusion of an identically appearing solution of sugar water will be intravenously administered.
Study: NCT02250612
Drug: 1 drop of 0.375% SYL040012 (bamosiran)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02250612
Drug: 1 drop of 0.750% SYL040012 (bamosiran)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02250612
Drug: 1 drop of 1.125% SYL040012 (bamosiran)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02250612
Drug: 1 drop of 1.5% SYL040012 (bamosiran)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03112382
Drug: zinc supplement plus vitamin A and E
Normalized name: vitamin A / vitamin E
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00896168
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
Study: NCT00563108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01238133
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01086046
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days.
Study: NCT03833999
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: overcoated placebo tablet, identical to the ondansetron
Study: NCT00963365
Drug: AZD6765
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose and single IV infusion of AZD6765
Study: NCT00963365
Drug: AZD6765
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
Study: NCT02804594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo taken three times daily
Study: NCT01280487
Drug: ZSTK474
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dosing for 21 days each cycle
Study: NCT03510572
Drug: [18F]PI-2620
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain
Study: NCT00485589
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral repeating dose
Study: NCT00485589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT05008146
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous, 1mg/Kg
Study: NCT00131677
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: study product taken daily
Study: NCT01314976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis.
Study: NCT00274768
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
Study: NCT00871377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: corn oil (n-6 fatty acids)
Study: NCT04142749
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total 90mg, By mouth, TID
Study: NCT01863277
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01863277
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02136277
Drug: Hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in 250ml boluses, until cardiac output has been optimised.
Study: NCT00613093
Drug: Temodar and O6-Benzylguanine (BG)
Normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle.
Study: NCT02376218
Drug: Hypertonic 50% dextrose pleurodesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural administration of 180ml of hypertonic dextrose solution.
Study: NCT01260350
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF) tablets administered orally once daily
Study: NCT01260350
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV/SOF fixed-dose combination (FDC) tablet administered once daily
Study: NCT01936064
Drug: Placebo + Cyclophosphamide - Epirubicin 6
Normalized name: epirubicin 0.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drugs for the treatment of breast cancer to be used with Placebo
Study: NCT00099788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV to oral transition.
Study: NCT01680978
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally daily, 6 weeks
Study: NCT05565976
Drug: Statins (Cardiovascular Agents)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h
Study: NCT05565976
Drug: Platelet Antiaggregant
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h
Study: NCT05565976
Drug: Antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previously established medical treatment for type 2 diabetes will be maintained.
Study: NCT02405585
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
Study: NCT03369236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo was administered as an oral tablet.
Study: NCT03568318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken orally once a day
Study: NCT03568318
Drug: Topical corticosteroids (TCS)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.~Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid.
Study: NCT00142493
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intralipid, saline, saline with multi-Vit solution
Study: NCT02530307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01490996
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care chemotherapy
Study: NCT02065336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00961090
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery
Study: NCT00568529
Drug: Capecitabine and Oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
Study: NCT03255993
Drug: SPH3127 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH3127 50mg
Study: NCT03255993
Drug: SPH3127 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH3127 100mg
Study: NCT03255993
Drug: Placebo matching to SPH3127 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to SPH3127 50mg
Study: NCT03255993
Drug: Placebo matching to SPH3127 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to SPH3127 100mg
Study: NCT03466021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching injection
Study: NCT03991884
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03991884
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01404442
Drug: placebo(distilled water
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
Study: NCT01653158
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-751,871 was given intravenously \[IV\] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year).
Study: NCT00421603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03983928
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT00765128
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Study: NCT00765128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Study: NCT03444870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as per the schedule specified in the respective arm.
Study: NCT04902534
Drug: placebo of Naoqingzhiming Tablets (without echinacoside)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose escalation and multiple dose escalation
Study: NCT03677817
Drug: NaCl 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
Study: NCT00848250
Drug: Angiotensin Converting Enzyme Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
Study: NCT03497442
Drug: Placebo Vehicle Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel
Study: NCT01170702
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
Study: NCT02535832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo CT Scan DXA scan Needle muscle biopsy
Study: NCT00304317
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
Study: NCT01343407
Drug: MK-1029 100 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
Study: NCT01343407
Drug: Placebo for MK-1029 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design.
Study: NCT01343407
Drug: Placebo for MK-1029 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
Study: NCT04619264
Drug: Papacarie
Approvals — FDA: no, EMA: no, PMDA: no
Description: First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
Study: NCT01500018
Drug: TC-5214 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT02432040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, made to look like the interventional drug
Study: NCT02034747
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01952535
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01952535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02656797
Drug: Topical Amphotericin-B 0.4% liposomal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Amphotericin-B 0.4% liposomal gel
Study: NCT02672111
Drug: CAM2038 q1w or q4w exposure to SL BPN/NX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02672111
Drug: CAM2038 q1w or q4w new to BPN treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00467025
Drug: AMG 386 placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 placebo IV
Study: NCT03930641
Drug: RTH258
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg in prefilled syringe
Study: NCT03641547
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 \& B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
Study: NCT01613547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days
Study: NCT00671580
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: as directed
Study: NCT02327221
Drug: Ovasave
Approvals — FDA: no, EMA: no, PMDA: no
Description: During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
Study: NCT02327221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
Study: NCT00589979
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Patch
Study: NCT02662985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
Study: NCT01486004
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
Study: NCT01486004
Drug: Ovysmen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
Study: NCT02056717
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of normal saline 2 mL IV 1 h before UAE
Study: NCT00931476
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no